NOCD receives $34M funding, investors include Cigna and Kaiser Permanente
This Series B round of funding for the startup was led by Cigna Ventures and 7wireVentures, with participation from Longitude Capital, Kaiser Permanente Ventures, F-Prime Capital, Eight Roads Capital, and Health Enterprise Partners. It brings the total funding of NOCD to $84M. NOCD – Company Overview NOCD is the world’s leading provider of treatment for…
